Latest news

Adalvo is ready to submit the DCP application for Dimethyl Fumarate gastro-resistant tablets (30mg and 120mg), targeting the treatment of moderate to severe plaque psoriasis in adult patients.   With the...

Adalvo announces the Day 1 launch of Ticagrelor across key European markets, marking a major milestone in the company’s global growth strategy and solidifying its role as a supply chain...

Adalvo announces the signing of an exclusive licensing agreement with Formosa Pharmaceuticals for the commercialisation of Clobetasol Propionate Ophthalmic Suspension, 0.05% in Europe and Brazil. The product features a patent-protected,...

Adalvo confirms a successful pivotal BE outcome for Dimethyl Fumarate 120mg gastro-resistant tablets under fed conditions, advancing its position in supporting partner access to this high-value dermatology asset.  Dimethyl Fumarate is an...

Adalvo announces the first-to-market launch of Pregabalin ER (Extended Release) tablets in Poland, in partnership with Exeltis.   With this launch, Adalvo further strengthens its position as the first and only...

Adalvo announces continued progress in the development of its Mirabegron/Solifenacin fixed-dose combination product, targeting unmet clinical needs in the treatment of overactive bladder (OAB) syndrome.  The formulation integrates Mirabegron and Solifenacin...

Adalvo has progressed into the pilot BE study phase for Apalutamide, with results expected by June 2025, marking a key step towards submission and Day 1 launch readiness in major...

Adalvo and Gedeon Richter have entered into a strategic co-development and license agreement for a proposed bioequivalent to Semaglutide, a GLP-1 receptor agonist indicated for chronic weight management. This collaboration is...

Adalvo has finalized a licensing and supply agreement with Daiichi Sankyo in Brazil, marking a significant milestone for both companies. This partnership aims to leverage Adalvo’s expertise in the central nervous...

Adalvo has submitted the DCP for Tofacitinib 11mg ER, marking a step forward in the expansion of our specialty generics portfolio.  Designed as an extended-release formulation of the reference brand Xeljanz,...

Adalvo’s DCP for Tacrolimus 0.03% and 0.1% Ointment is making significant progress, with closure planned for Q3 2025. Engineered for effective dermal delivery, Tacrolimus Ointment represents a highly specialized R&D achievement,...

Adalvo joins the global community in celebrating World Intellectual Property Day, recognising the vital role of IP in advancing pharmaceutical development. At Adalvo, our strong IP strategy is key to delivering...

Adalvo will submit the DCP for Fidaxomicin 200mg tablets in June 2025, highlighting our commitment to expanding access to high-value antibiotic treatments across global markets, including the U.S.  Based on the...

Adalvo, in collaboration with its strategic partner CNX Therapeutics, has launched Nitrofurantoin Modified Release Tablets in the Netherlands, marking the first generic entry in these markets. Developed in-house, this milestone comes...

Adalvo announces the completion of its global dossier for Dolutegravir, a high-value antiretroviral therapy widely recognized for its pivotal role in HIV treatment.   Dolutegravir, a blockbuster anti-HIV product, is a...

Adalvo continues to expand its specialty generics portfolio with the development of Voclosporin Soft Gel Capsules, a calcineurin inhibitor (CNI) indicated for the treatment of active lupus nephritis (LN) in...

Adalvo, in collaboration with its regional partner, has successfully launched Solifenacin/Tamsulosin in various LATAM markets, marking the first generic entry of this therapy in the region. More launches across the region...

Adalvo is on track to complete the global dossier for Ceftazidime + Avibactam by year-end. Developing this complex antibiotic combination required overcoming significant challenges, including securing limited API sources and...